The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase Ib study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC).
 
Andrew X. Zhu
Consulting or Advisory Role - AstraZeneca; Bayer; Eisai; Exelixis; Lilly; Merck; Roche/Genentech
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst)
 
Richard S. Finn
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; CStone Pharmaceuticals; Eisai; Exelixis; Genentech/Roche; Lilly; Merck; Novartis; Pfizer
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Expert Testimony - Novartis
 
Masafumi Ikeda
Honoraria - Astellas Pharma; Bayer Yakuhin; Dainippon Sumitomo Pharma; EA Pharma; Eisai; Gilead Sciences; Kaken Pharmaceutical; Lilly Japan; MSD; Mylan; Novartis; Otsuka; SERVIER; Taiho Pharmaceutical; Teijin Pharma; Yakult Pharmaceutical
Consulting or Advisory Role - ASLAN Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; Eisai; Lilly Japan; Micron; MSD; Novartis; Ono Pharmaceutical; SERVIER; Shire; Teijin Pharma
Research Funding - ASLAN Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer Yakuhin (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Eisai (Inst); J-Pharma (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); NanoCarrier (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Takeda (Inst); Yakult Pharmaceutical (Inst)
 
Max W. Sung
Consulting or Advisory Role - Bayer; Eisai; Exelixis
 
Ari David Baron
Speakers' Bureau - Abbvie; Amgen; Bristol-Myers Squibb; Eisai; Genentech/Roche; Johnson & Johnson; Lilly; Merck
 
Masatoshi Kudo
Honoraria - Bayer; Eisai; MSD
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; MSD; Ono Pharmaceutical
Research Funding - Abbvie (Inst); EA Pharma (Inst); Eisai (Inst); Gilead Sciences (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Takuji Okusaka
Honoraria - Abbvie; AstraZeneca; Bayer; Celgene; Daiichi Sankyo; EA pharma; Eisai; Fujifilm; Lilly; Meiji Seika Kaisha; MSD; Mundipharma; Nippon Shinyaku; Novartis; Ono Pharmaceutical; Pfizer; SERVIER; Shire; Taiho Pharmaceutical; Takeda; Teijin Pharma; Yakult Honsha
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Dainippon Sumitomo Pharma; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); Baxter (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); MSD (Inst); NanoCarrier (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Takara Bio
 
Masahiro Kobayashi
Honoraria - Eisai
 
Hiromitsu Kumada
Honoraria - Abbvie; Eisai; Gilead Sciences; MSD; Sumitomo Group
 
Shuichi Kaneko
Honoraria - Abbvie; ASKA Pharmaceutical; Astellas Pharma; Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; EA Pharma; Eisai; Eisai; Gilead Sciences; Kowa; Lilly; Mitsubishi Tanabe Pharma; Miyarisan Pharmaceutical; Mochida Pharmaceutical Co. Ltd.; MSD; Mylan; Otsuka; Sumitomo Group; Sysmex; Taiho Pharmaceutical; Taisho Toyama Pharma; Takeda
Consulting or Advisory Role - Bayer; Hokkoku Bank; Kowa
Research Funding - Abbott Vascular Japan; Abbvie; Alexion Pharmaceuticals; ASKA Pharmaceutical; Astellas Pharma; Bayer; Biotronik International; Boston Scientific; Bristol-Myers Squibb; Central Medical; Daiichi Sankyo; EA Pharma; Eisai; Gilead Sciences; Japan Lifeline; Kataoka; Kiowa Kirin; Kowa; Lilly; Medtronic; Mitsubishi Tanabe Pharma; MSD; Mylan; Nihon Medi-Physics; Nippon Boehringer Ingelheim; Nippon Kayaku; Novartis; Novo Nordisk; Ono Pharmaceutical; Otsuka; Pfizer; Sanofi; Sanwa Kagaku Kenkyusho; Shionogi; St. Jude Medical Japan; Sumitomo Group; Taiho Pharmaceutical; Taisho Toyama Pharma; Takeda; Teijin Pharma; TERUMO; Tomiki Medical Instruments; Zeon Medical; Zeria Pharmaceutical
 
Marc Pracht
Consulting or Advisory Role - Eisai; MSD
 
Konstantin Mamontov
Consulting or Advisory Role - Bayer; Merck
Speakers' Bureau - Merck
Travel, Accommodations, Expenses - Bayer; Eisai; Merck
 
Tim Meyer
Consulting or Advisory Role - Beigene; Bristol-Myers Squibb; BTG; Eisai; Ipsen; MSD; Roche
Research Funding - Bayer (Inst); BTG (Inst); Ipsen (Inst)
 
Kalgi Mody
Employment - Eisai
 
Tomoki Kubota
Employment - Eisai
 
Corina E. Dutcus
Employment - Eisai
 
KENICHI SAITO
Employment - Eisai
 
Abby B. Siegel
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Leonid Dubrovsky
Employment - Merck
Stock and Other Ownership Interests - Merck
Travel, Accommodations, Expenses - Merck
 
Josep M Llovet
Consulting or Advisory Role - Bayer; Blueprint Medicines; Bristol-Myers Squibb; Can-Fite BioPharma; Celsion; Eisai; Exelixis; Fortress Biotech; Glycotest; Incyte; Leerink; Lilly; Merck; Midatech Pharma; Navigant Consulting; Nucleix; Spring Bank
Research Funding - Bayer Schering Pharma (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Ipsen (Inst)
Travel, Accommodations, Expenses - Bayer